Evaluating and treating the prodromal stage of schizophrenia

Current Psychiatry Reports

Volumn 6, Issue 4, 2004, Pages 289-295

  Perkins, Diana O ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; PLACEBO; RISPERIDONE;

ADOLESCENT; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; FAMILY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PSYCHOSIS; PSYCHOTHERAPY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SYMPTOMATOLOGY; WEIGHT GAIN;

EID: 4444261797     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-004-0079-8     Document Type: Review

References (44)

1. Hafner H, an der Heiden W: Epidemiology of schizophrenia. Can J Psychiatry 1997, 42:139-151.
2. Yung AR, McGorry PD: The initial prodrome in psychosis: descriptive and qualitative aspects. Aust N Z J Psychiatry 1996, 30:587-599.
3. Yung AR, McGorry PD: The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull 1996, 22:353-370.
4. Gross G: The onset of schizophrenia. Schizophr Res 1997, 28:187-198.
5. Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F: Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001, 58:158-164.
6. Tan HY, Ang YG: First-episode psychosis in the military: a comparative study of prodromal symptoms. Aust N Z J Psychiatry 2001, 35:512-519.
7. Perkins DO, Leserman J, Jarskog LF, et al.: Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophr Res 2000, 44:1-10.
8. Fuller R, Nopoulos P, Arndt S, et al.: Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. Am J Psychiatry 2002, 159:1183-1189.
9. Ang YG, Tan HY: Academic deterioration prior to first episode schizophrenia in young Singaporean males. Psychiatry Res 2004, 121:303-307.
10. Addington J, van Mastrigt S, Hutchinson J, Addington D: Pathways to care: help seeking behaviour in first episode psychosis. Acta Psychiatr Scand 2002, 106:358-364.
11. McGorry PD, McFarlane C, Patton GC, et al.: The prevalence of prodromal features of schizophrenia in adolescence: a preliminary survey. Acta Psychiatr Scand 1995, 92:241-249.
12. Tien AY: Distributions of hallucinations in the population. Soc Psychiatry Psychiatr Epidemiol 1991, 26:287-292.
13. van Os J: Is there a continuum of psychotic experiences in the general population? Epidemiol Psichiatr Soc 2003, 12:242-252.
14. Phillips LJ, Yung AR, McGorry PD: Identification of young people at risk of psychosis: validation of Personal Assessment and Crisis Evaluation Clinic intake criteria. Aust N Z J Psychiatry 2000, 34(suppl):S164-169.
15. Miller TJ, McGlashan TH, Rosen JL, et al.: Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull 2003, 29:703-715.
16. Hambrecht M, Lammertink M, Klosterkotter J, et al.: Subjective and objective neuropsychological abnormalities in a psychosis prodrome clinic. Br J Psychiatry Suppl 2002, 43:S30-S37.
17. Yung AR, McGorry PD, McFarlane CA, et al.: Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull 1996, 22:283-303.
18. Yung AR, Phillips LJ, McGorry P, et al.: The Comprehensive Assessment of At-risk Mental States (CAARMS). Victoria, Australia: University of Melbourne; 2000.
19. Miller TJ, McGlashan TH, Rosen JL, et al.: Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 2002, 159:863-865.
20. Gross, G, Huber G, Klosterkotter J, Linz M: Bonn Scale for the Assessment of Basic Symptoms. New York: Springer-Verlag; 1987.
21. Ruhrmann S, Schultze-Lutter F, Klosterkotter J: Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry 2003, 36(suppl):S162-S167.
22. Yung AR, Phillips LJ, Yuen HP, McGorry PD: Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res 2004, 67:131-142.
23. Morrison AP, French SA, Walford L, et al.: A randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultra-high risk. Schizophr Res 2004, 67:7
24. Woods SW, Miller TJ, McGlashan TH: The prodromal patient: both symptomatic and at risk. CNS Spectrums 2001, 6:223-232.
25. Haak DC, Perkins DO, Graham KA, et al.: Risk of psychosis in individuals experiencing prodromal symptoms. Schizophr Res 2004, 67:33.
26. Perkins DO: Markers for schizophrenia. Am J Psychiatry 2000, 157:1527.
27. Yung AR, Phillips LJ, Yuen HP, et al.: Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res 2003, 60:21-32.
28. Niemi LT, Suvisaari JM, Tuulio-Henriksson A, Lonnqvist JK: Childhood developmental abnormalities in schizophrenia: evidence from high-risk studies. Schizophr Res 2003, 60:239-258.
29. Cosway R, Byrne M, Clafferty R, et al.:Neuropsychological change in young people at high risk for schizophrenia: results from the first two neuropsychological assessments of the Edinburgh High Risk Study. Psychol Med 2000, 30:1111-1121.
30. Rabinowitz J, Reichenberg A, Weiser M, et al.: Cognitive and behavioural functioning in men with schizophrenia both before and shortly after first admission to hospital: cross-sectional analysis. Br J Psychiatry 2000, 177:26-32.
31. Hawkins KA, Addington J, Keefe RS, et al.: Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophr Res 2004, 67:115-122.
32. Wood SJ, Pantelis C, Proffitt T, et al.: Spatial working memory ability is a marker of risk-for-psychosis. Psychol Med 2003, 33:1239-1247.
33. Brewer WJ, Wood SJ, McGorry PD, et al.: Impairment of olfactory identification ability in individuals at ultra-high risk for psychosis who later develop schizophrenia. Am J Psychiatry 2003, 160:1790-1794.
34. Pantelis C, Velakoulis D, McGorry PD, et al.: Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003, 361:281-288.
35. McGorry PD, Yung A, Phillips L: Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophr Res 2001, 51:17-29.
36. Perkins DO, Lieberman JA, Gu H, et al.: Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective, and schizophreniform disorders. Br J Psychiatry 2004, in press.
37. DelBello MP, Soutullo CA, Hendricks W, et al.: Prior stimulant treatment in adolescents with bipolar disorder: association with age at onset. Bipolar Disord 2001, 3:53-57.
38. McGlashan TH, Zipursky RB, Perkins D, et al.: The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis, I: study rationale and design. Schizophr Res 2003, 61:7-18.
39. Miller TJ, Zipursky RB, Perkins D, et al.: The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis, II: baseline characteristics of the "prodromal" sample. Schizophr Res 2003, 61:19-30.
40. McGlashan TH, Zipurksy RB, Perkins DO, Addington J: Olanzapine for treatment of the schizophrenia prodrome: 2-year results of a randomized placebo-controlled study. Schizophr Res 2004, 67:164.
41. Woods SW, Breier A, Zipursky RB, et al.: Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry 2003, 54:453-464.
42. McGorry PD, Yung AR, Phillips LJ, et al.: Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002, 59:921-928.
43. Sikich L, Hamer RM, Bashford RA, et al.: A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004, 29:133-145.
44. Lehman AF, Lieberman JA, Dixon LB, et al.: Practice guideline for the treatment of patients with schizophrenia: second edition Am J Psychiatry 2004, 161:1-56.